Mind-altering substances are (still) falling short in clinical trials

Two new studies published this week cast significant doubt on the highly-touted therapeutic potential of psychedelics like psilocybin for treating depression. A German trial with 144 patients found that while psilocybin showed some improvement, it was not significantly better than an active placebo when both patients and investigators were blinded. A separate meta-analysis by Balázs Szigeti at UCSF, which assessed 24 open-label trials, concluded psychedelics were no more effective than traditional antidepressants. These findings directly challenge the explosive hype surrounding these substances as breakthrough mental health treatments.

The core issue plaguing this research is the near-impossibility of 'blinding'—preventing participants from knowing if they received the drug or a placebo. The intense hallucinogenic experience is a dead giveaway. This creates a powerful expectation bias, inflating the perceived benefit in the drug group. Conversely, it triggers what Szigeti calls a 'knowcebo effect' in the placebo group, where the disappointment of not receiving the psychedelic worsens their outcomes. This methodological flaw makes it extremely difficult to isolate the true pharmacological effect from the profound psychological experience, suggesting current evidence may be overstating the drugs' efficacy.